Jump to content

Draft:Annovis Bio

From Wikipedia, the free encyclopedia

Annovis Bio, Inc. is a biotechnology company focused on developing treatments for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD).[1] The company is headquartered in Malvern, Pennsylvania and was founded in 2008 by Dr. Maria Maccecchini. Annovis Bio is publicly listed on the New York Stock Exchange (NYSE) under the ticker symbol ANVS.[2] Its lead drug candidate buntanetap (previously known as posiphen) is an investigational treatment for Alzheimer's and Parkinson's in Phase 3 clinical development.[3]

History

[edit]

The company's investigational drug, buntanetap, was discovered through a program funded by the National Institutes of Health (NIH) and later licensed to Axonyx. After Axonyx merged with TorreyPines Therapeutics, Dr. Maccecchini acquired the rights to buntanetap and continued its development through a newly founded company - originally named QR Pharma - which was established in 2008.[4] In 2019, QR Pharma was renamed Annovis Bio, and in January 2020 the company completed an initial public offering (IPO) on the NYSE, raising approximately $13.8 million.[5] Dr. Maccecchini has served as the company's Chief Executive Officer (CEO) since its inception.

Scientific approach

[edit]

Annovis Bio's research is based on the hypothesis that the inhibition of the overproduction of multiple neurotoxic proteins, which are prone to aggregation, might slow the progression of neurodegenerative diseases.[6][7] Neurodegenerative disorders like Alzheimer's and Parkinson's are hypothesized to be driven by the accumulation of misfolded or aggregating proteins, including amyloid-beta, tau, alpha-synuclein, and TDP-43, that can disrupt communication between cells, impair neuronal function, cause inflammation, and ultimately lead to death of nerve cells.[8][9]

Lead drug candidate

[edit]

Buntanetap (previously known as posiphen) is an orally administered small molecule and a (+)-enantiomer of phenserine, but unlike phenserine it does not inhibit acetylcholinesterase.[3] Buntanetap is hypothesized to act by strengthening the interaction between mRNAs of neurotoxic proteins and iron regulatory protein 1 (IRP1), preventing their translation (essential part of protein synthesis) by ribosomes.[10][11] Through this mechanism, the drug is believed to simultaneously inhibit the synthesis of multiple proteins that aggregate in neurodegenerative diseases. Preclinical and early clinical studies have shown an association between treatment with buntanetap and reduced levels of amyloid precursor protein (APP) and amyloid-beta,[12][13] tau,[14] alpha-synuclein,[15] and TDP-43,[16] as well as huntingtin and prion protein.[17][18]

Clinical development

[edit]

Phase 1 and 2 studies in humans have assessed buntanetap's safety, tolerability, and effects on biomarkers in early Alzheimer's and Parkinson's patients.[19][20][21] In a Phase 2/3 trial, buntanetap was tested in mild-to-moderate Alzheimer's patients for 3 months.[22] The study did not meet its primary endpoints, but the company reported an improvement in patients with mild-stage disease compared to placebo as part of a secondary analysis. In a Phase 3 trial, buntanetap was tested in early Parkinson's patients for 6 months.[23][24][25] The company reported improved cognitive function in patients receiving buntanetap compared to placebo and improved motor function in certain subpopulations. In 2025, Annovis Bio launched a Phase 3 trial of buntanetap in early Alzheimer's patients to evaluate clinical efficacy and safety.[26][27] The company also began an open-label extension study in Parkinson's patients in 2026 to gather long-term data.[28] As of 2026, buntanetap remains an investigational drug and has not received regulatory approval for any indication.

See also

[edit]

References

[edit]
  1. ^ "Annovis Bio". CNBC. Retrieved 12 January 2026.
  2. ^ "NYSE Annovis Bio Inc". nyse.com.
  3. ^ a b "Buntanetap". Alzforum. 23 July 2024. Retrieved 10 January 2026.
  4. ^ Comer, Ben (1 October 2024). "Annovis Bio: Against The Grain In Alzheimer's Disease". LIfeScienceLeader.com. Retrieved 10 January 2026.
  5. ^ George, John (31 January 2020). "Inside Annovis Bio's $13.8 million IPO". Philadelphia Business Journal. Retrieved 12 January 2026.
  6. ^ Zhou, Zhi Dong (23 October 2017). "Iron regulatory protein (IRP)-iron responsive element (IRE) signaling pathway in human neurodegenerative diseases". Molecular Neurodegeneration. 12 (1) 75. doi:10.1186/s13024-017-0218-4. PMC 5654065. PMID 29061112.
  7. ^ Cahill, Catherine (July 2009). "Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases". Biochimica et Biophysica Acta (BBA) - General Subjects. 1790 (7): 615–628. doi:10.1016/j.bbagen.2008.12.001. PMC 3981543. PMID 19166904.
  8. ^ Wennberg, Alexandra (21 January 2019). "The influence of tau, amyloid, alpha-synuclein, TDP-43 and vascular pathology in clinically normal elderly individuals". Neurobiology of Aging. 77: 26–36. doi:10.1016/j.neurobiolaging.2019.01.008. PMC 6486870. PMID 30776649.
  9. ^ Wu, Wei-long (19 May 2025). "Molecular mechanisms of excitotoxicity and their relevance to the pathogenesis of neurodegenerative diseases—an update". Acta Pharmacologica Sinica. 46 (12): 3129–3142. doi:10.1038/s41401-025-01576-w. PMC 12644896. PMID 40389567.
  10. ^ Bandyopadhyay, Sanghamitra (31 July 2013). "Novel 5' untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for down syndrome and Alzheimer's disease". PLOS ONE. 8 (7): e65978. Bibcode:2013PLoSO...865978B. doi:10.1371/journal.pone.0065978. PMC 3729844. PMID 23935819.{{cite journal}}: CS1 maint: article number as page number (link)
  11. ^ Mikkilineni, Sohan (2012). "The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression". Parkinson's Disease. 2012. doi:10.1155/2012/142372. PMC 3368596. PMID 22693681.
  12. ^ Galasko, Douglas (5 July 2024). "A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer's Disease". Alzheimer's Research & Therapy. 16 (1) 151: 161. doi:10.1186/s13195-024-01490-z. PMC 11225352. PMID 38970127.
  13. ^ Chen, Xu-Qiao (February 2021). "Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model". Alzheimer's & Dementia. 17 (2): 271–292. doi:10.1002/alz.12185. PMC 7984396. PMID 32975365.
  14. ^ Maccecchini, Maria (September 2012). "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans". Journal of Neurology, Neurosurgery and Psychiatry. 83 (9): 894–902. doi:10.1136/jnnp-2012-302589. PMC 3415310. PMID 22791904.
  15. ^ Rogers, Jack (March 2011). "The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen". Journal of Neural Transmission. 118 (3): 493–507. doi:10.1007/s00702-010-0513-5. PMC 6625511. PMID 21221670.
  16. ^ Lobo, Andrea (27 November 2023). "Buntanetap lowered TDP-43 blood levels in people with Parkinson's". Parkinson's News Today. Retrieved 12 January 2026.
  17. ^ Chen, Xu-Qiao (7 December 2021). "Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression". Pharmaceutics. 13 (12): 2109. doi:10.3390/pharmaceutics13122109. PMC 8708689. PMID 34959389.
  18. ^ Fang, Chen (2023). "Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients". The Journal of Prevention of Alzheimer's Disease. 10 (1): 25–33. doi:10.14283/jpad.2022.84. PMID 36641607.
  19. ^ "Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment". ClinicalTrials.gov. 22 February 2010. Retrieved 12 January 2026.
  20. ^ "Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients". ClinicalTrials.gov. 24 August 2020. Retrieved 12 January 2026.
  21. ^ "Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease (DISCOVER)". ClinicalTrials.gov. 16 October 2016. Retrieved 12 January 2026.
  22. ^ "A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD". ClinicalTrials.gov. 17 January 2023. Retrieved 12 January 2026.
  23. ^ "A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD". ClinicalTrials.gov. 3 May 2022. Retrieved 12 January 2026.
  24. ^ Meglio, Marco (3 July 2024). "Buntanetap Improves Motor, Nonmotor and Cognitive Symptoms of Parkinson Disease in Phase 3 Study". NeurologyLive.com. Retrieved 10 January 2026.
  25. ^ Singh, Vandana (17 November 2025). "Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients". Benzinga.com. Retrieved 10 January 2026.
  26. ^ "A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD". ClinicalTrials.gov. 29 November 2025. Retrieved 10 January 2026.
  27. ^ "Annovis begins treatment of subjects in Alzheimer's trial". ClinicalTrialsArena.com. 6 February 2025. Retrieved 10 January 2026.
  28. ^ "A Study of Buntanetap in Participants With PD". ClinicalTrials.gov. 16 December 2025. Retrieved 10 January 2026.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Annovis_Bio&oldid=1356081297"